Alkermes Plc (NASDAQ:ALKS) has been assigned a consensus recommendation of “Hold” from the seventeen analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $56.10.
ALKS has been the topic of several analyst reports. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Alkermes in a report on Monday, July 2nd. BidaskClub upgraded shares of Alkermes from a “hold” rating to a “buy” rating in a report on Wednesday, June 13th. B. Riley initiated coverage on shares of Alkermes in a report on Wednesday, June 6th. They issued a “buy” rating and a $60.00 target price on the stock. Citigroup upgraded shares of Alkermes from a “neutral” rating to a “buy” rating in a report on Thursday, May 31st. Finally, Zacks Investment Research upgraded shares of Alkermes from a “hold” rating to a “buy” rating and set a $52.00 target price on the stock in a report on Wednesday, May 30th.
In related news, Director Floyd E. Bloom sold 20,000 shares of the firm’s stock in a transaction on Monday, July 16th. The shares were sold at an average price of $43.95, for a total transaction of $879,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Paul J. Mitchell sold 1,000 shares of the firm’s stock in a transaction on Tuesday, July 3rd. The stock was sold at an average price of $41.86, for a total transaction of $41,860.00. Following the sale, the director now owns 8,000 shares in the company, valued at $334,880. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,000 shares of company stock worth $1,009,120. 5.34% of the stock is currently owned by company insiders.
Large investors have recently modified their holdings of the stock. Rhumbline Advisers increased its stake in Alkermes by 2.0% in the 2nd quarter. Rhumbline Advisers now owns 163,757 shares of the company’s stock valued at $6,740,000 after buying an additional 3,236 shares during the last quarter. Teacher Retirement System of Texas increased its stake in Alkermes by 6.0% in the 2nd quarter. Teacher Retirement System of Texas now owns 41,859 shares of the company’s stock valued at $1,723,000 after buying an additional 2,387 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Alkermes in the 2nd quarter valued at $3,398,000. State of New Jersey Common Pension Fund D increased its stake in Alkermes by 31.0% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 190,000 shares of the company’s stock valued at $7,820,000 after buying an additional 45,000 shares during the last quarter. Finally, Brinker Capital Inc. increased its stake in Alkermes by 21.1% in the 1st quarter. Brinker Capital Inc. now owns 29,010 shares of the company’s stock valued at $1,681,000 after buying an additional 5,058 shares during the last quarter.
ALKS traded down $0.04 during mid-day trading on Friday, hitting $39.66. The stock had a trading volume of 488,303 shares, compared to its average volume of 463,429. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.62 and a current ratio of 2.92. The firm has a market cap of $6.19 billion, a PE ratio of -107.19 and a beta of 1.72. Alkermes has a 1-year low of $39.40 and a 1-year high of $71.22.
Alkermes (NASDAQ:ALKS) last posted its earnings results on Thursday, July 26th. The company reported $0.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.40. The company had revenue of $304.64 million for the quarter, compared to analyst estimates of $261.58 million. Alkermes had a negative net margin of 13.81% and a negative return on equity of 0.29%. The business’s revenue for the quarter was up 39.2% compared to the same quarter last year. During the same period last year, the business posted $0.01 earnings per share. equities analysts forecast that Alkermes will post -0.67 EPS for the current fiscal year.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes.
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.